Pharmacokinetic Study of Ondansetron Administered as IR (Zofran) and MR (EUR1025)

The objective of this study is to evaluate the pharmacokinetics (PK) of ondansetron administered as a novel modified-release formulation (EUR1025 24 mg) as well as the immediate-release formulation (Zofran 8 mg) after single and multiple oral dose administration under fasting and fed conditions based on the requirements of the respective indications. The safety profile of each treatment will also be assessed by recording the nature, severity, frequency, duration and relation to the treatment of any adverse events.

Inclusion criteria

• Male and female volunteers
• Non- or ex-smokers
• At least 21 years of age but not older than 55 years
• Body mass index targeted to be at least 18.5 and less than 30 kg/m2.
• Acceptable lab tests
• Normal 12 lead ECG
• Negative human chorionic gonadotropin (hCG) for females.

Exclusion criteria

• No known hypersensitivity to Ondansetron or any related products
• No presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption
• No presence of significant heart disease or disorder discovered on screening ECG
• Not pregnant
• No alcohol or drug abuse history
• No use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP)
• No previous Investigational Product (in another clinical trial) or donated 50 ml or more of blood in the previous 28 days before day 1 of this study